News | SCAI | May 17, 2020

Cindy Grines Becomes SCAI President

Cindy Grines Becomes SCAI President in 2020. #SCAI2020

May 17, 2020 — Cindy Grines, M.D., MSCAI, a world-renowned physician credited for pioneering percutaneous coronary intervention (PCI) for heart attacks, has assumed the office of president of the Society for Cardiovascular Angiography and Interventions (SCAI). Grines’ tenure as president officially begans Saturday, May 16, during the SCAI 2020 Scientific Sessions Virtual Conference. Grines is the third female interventionalist to lead the society.

“Dr. Grines is a luminary in the field of interventional cardiology, and we are thrilled she will serve as SCAI president for the upcoming year,” said Francesca Dea, CAE, chief executive officer of SCAI. “During this tumultuous time in global history it will be invaluable to have Dr. Grines’ vast expertise and visionary mindset help steer a course for the future of interventional cardiology and how cath lab teams adapt their patient care. Her contributions and experience will ensure that SCAI advances in a way to best serve our members and their patients.”

A longtime, devoted member of SCAI, Grines has been an inaugural supporter of SCAI Women in Innovations (SCAI-WIN). SCAI-WIN is a worldwide effort devoted to improving the overall approach to the medical treatment of women with cardiovascular disease, as well as increasing the quality and scope of professional opportunities offered to female interventional cardiologists.

Currently serving as the chief scientific officer of the Northside Cardiovascular Institute in Atlanta, Grines has a long history of research, publications, and clinical trial design with more than 500 publications and numerous book chapters and review chapters. Grines serves on the editorial boards of several major journals both nationally and internationally and has co-edited several medical handbooks. Grines received her doctor of medicine from Ohio State University College of Medicine and completed her cardiology fellowship at the University of Michigan.

During her presidency, Grines plans to focus on diversity and inclusiveness across the Society, enhanced membership engagement, proactive digital education and access, continued engagement with our sister organizations, and to further increase SCAI’s visibility globally through educational and case-reviewed programs both regionally and internationally.

Other incoming officers of SCAI’s 2020-21 Executive Committee include:
   • Timothy D. Henry, M.D., MSCAI, as president-elect;
   • Sunil V. Rao, M.D., FSCAI, as vice president; 
   • George D. Dangas, M.D., MSCAI, as secretary; 
   • Peter L. Duffy, M.D., FSCAI, as treasurer; 
   • Arnold H. Seto, M.D., FSCAI, as associate treasurer; and 
   • Ehtisham Mahmud, M.D., FSCAI, as immediate past-president.

For more information: www.scai.org
 

Related Content

A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect
Feature | Cath Lab | October 18, 2020
October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benef
A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin capped fibrous atheroma (TCFA). #TCTconnect #TCT2020

A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin cap fibro-atheroma (TCFA).

News | Cath Lab | October 18, 2020
October 18, 2020 – Data from the...
The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions. #TCT2-0

The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions.

Feature | Cath Lab | October 16, 2020
October 15, 2020 — Shockwave Medical's Intravascular Lithotripsy (IVL) system to treat severely calcified coronary ar
Videos | Cath Lab | October 16, 2020
This is an example pf the Shockwave Medical Intravascular Lithotripsy (IVL) catheter system designed to break up heav
Videos | Cath Lab | July 15, 2020
Richard Botto, CVT, RCSA, chief cardiovascular technologist, division of cardiology, cardiac cath lab, offers an over
Videos | Cath Lab | July 13, 2020
The Vieussens’ arterial ring (VAR) is a connection between the conus artery and the left anterior descending (LAD) co
News | Cath Lab | July 06, 2020
July 6, 2020 — Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major
TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th